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Summary 
We analyzed an amino-terminal modification of p-amy- 
Ioid (A~) peptide in brain, using anti-Al~ antibodies that 
distinguish distinct molecular species. Examination of 
cortical sections from 28 aged individuals with a wide 
range in senile plaque density revealed that a molecu- 
lar species distinct from the standard A~ is deposited 
in the brain in a dominant and differential manner. This 
modified AI~ peptide (A~N3(pE)) starts at the 3rd amino- 
terminal residue of the standard AI~, glutamate, con- 
verted to pyroglutamate through intramolecular dehy, 
dration. Because plaques composed of A~N3(pE) are 
present in equivalent or greater densities than those 
composed of standard Ap bearing the first amino- 
terminal residue (AId.l) and because deposition of the 
former species appears to precede deposition of the 
latter, as confirmed with specimens from Down's syn- 
drome patients, the processes involved in A~N3(pE) pro- 
duction and retention may play an early and critical 
role in senile plaque formation. 
Introduction 
The correlation between the progressive deposition of 
13-amyloid (AI~) peptides in senile plaques in brain and the 
pathological onset of Alzheimer's disease (AD) indicates 
that AI~ metabolism is involved in the disease development 
as a critical factor (Selkoe, 1993; Mullan and Crawford, 
1993). Therefore, to clarify how the peptides are pro- 
cessed during the course of senile plaque formation and 
how their structures affect their pathogenic properties is 
an essential step toward understanding the pathological 
mechanism of AD. Because a subtle difference of 2 amino 
acid residues in the AI3 carboxy-terminal sequence drasti- 
cally alters their physicochemical parameters linked to 
plaque formation (Jarrett and Lansbury, 1993), caution is 
now requi~:ed so as not to overlook any in vivo modifica- 
tions that might potentially affect the AI3 pathogenicity. 
While information on carboxy-terminal variations and their 
roles is accumulating (Miller et al., 1993; Suzuki et al., 
1994; Iwatsubo et al., 1994), little is as yet known about 
modifications at the other end of the molecule, owing in 
part to technical obstacles. 
A number of reports have described the structures of 
AI~ peptides isolated from AD brains (Glenner and Wong, 
1984; Masters et al., 1985; Selkoe et al., 1986; Mori et 
al., 1992; Roher et al., 1993a, 1993b; Miller et al., 1993; 
Gowing et al., 1994). Although discrepancies exist de- 
pending on the purification procedures and analytical 
methods employed, we were particularly interested in the 
study by Mori et al. (1992) describing the consistent (15O/o - 
20%) presence of an AI~ peptide bearing an amino- 
terminal pyroglutamate (AI3N~pE)), in addition to the major 
species bearing the standard initial amino terminus (AI3N~), 
Because the amino terminus of the AI3N3(pE) peptide is 
blocked by internal actam (see Figure 1A), it is protected 
from the proteolytic action of aminopeptidases other than 
pyroglutamate-specific ones (McDonald and Barrett, 1986) 
and can thus remain stable in tissues. The peptide is also 
resistant o Edman degradation and is thus usually over- 
looked in chemical sequencing. Furthermore, the AI~N3(pE )
peptide is also likely to possess altered physicochemical 
characteristics because the conversion of AI3N1 to AI3N3(pE) 
results in the loss of one positive and two negative charges 
per molecule. These unique properties of AI3N3(pE) led us to 
assume that a possible involvement of this amino-terminal 
modification in amyloid plaque formation had not yet been 
examined fully. We have therefore conducted an in situ 
analysis of this amino-terminal modification so that the 
results might not be influenced by purification procedures 
and that spatial information concerning the localization of 
AI3N3(pE) as compared with AI3N1 might be obtained. 
Results 
Antibodies Specific to Distinct Amino-Terminal 
Structures of AJ~ 
As a tool to distinguish between AI3N1 and AI3N:~pE), shown 
in Figure 1A, we developed antibodies of novel character- 
istics: anti-AI31.5 for the former (Saido et al., 1994a) and 
anti-AI33(pE~7 for the latter. The unique methodology used to 
produce such proteolytic product-specific antibodies was 
developed in our previous studies (Saido et al., 1992, 
1993, 1994b). Figures 1 B and 1C show the specificity of 
these antibodies and another anti-A[~ antibody, anti-AI31_28 
(Kanemaru et al., 1990). In Western blot analysis, the anti- 
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Figure 1, Amino-Terminal Modification of Ap Peptides and Modifica- 
tion-Specific Anti-Ap Antibodies 
(A) The amino-terminal spartylalanyl moiety of the standard AI~., pep- 
tide is removed by mono- or dipeptidylaminopepfidase(s) to yield a new 
terminal glutamate residue, which readily converts to the pyro-form 
(A[~)  through intramolecular dehydration. Note that this modifica- 
tion results in the loss of one positive and two negative charges. The 
product is unique in being resistant to most aminopeptideses and to 
chemical sequencing, pE, pyroglutamate. 
(13) Synthetic peptides (50 ng) corresponding to AI~I~ (lane 1) and 
. ~  (lane 2) were subjected to Western blot analysis on 5%-20% 
gradient gel using the indicated antibodies. 
((3) The Ap,~ and A ~  peptides (20 ng) were subjected to dot blot 
analysis using the anti-A[~ antibodies as indicated. Antibody binding 
was performed in the absence (-)  or presence (+) of the antigenic 
hapten peptide for the anti-A.8,~ antibody, DAEFRC (40 pM), as pre- 
viously descdbed (Saido et al., 1994a). 
Ap~.5 and anti -Al~7 antibodies recognized Al~o and 
Ap~-.o peptides, respectively, in a m nner strictly exclu- 
sive of each other. The primary structures of the synthetic 
peptides were verified by mass spectroscopy (electron 
spray) and peptide mapping. These results were con- 
firmed further by dot blot analysis (Figure 1C), in which 
binding of anti-APl~ to the Ap~ peptide was blocked by 
the A131~ peptide, whereas the binding of anti-Apa~-~7 to
the AI~=E)~o peptide was not. 
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Figure 2. Reactivity of Various Anti-A~ Antibodies with Standard and 
Modified Ap Peptides 
The standard and modified synthetic Ap peptides-- 1-40, l(isomerized 
D)-40, l(racemized D)-40, 3(pE)-40,17-40,1-42, and 17-28--were sub- 
jected to dot blot analysis using the indicated antibodies as described 
in the legend to Figure 1C. The labels l(isomerized D)-40 and l(race- 
mized D)-40 stand for AI~-~ peptides possessing isoaspartate and 
racamized aspartate at the amino terminus, respectively. 
The anti-Al~l-~ antibody was originally used as a positive 
control antibody that would recognize both A I~ and 
AI~E~O peptides because of the larger epitope range of AI~ 
that it was expected to cover. Unexpectedly, this antibody 
bound only to A I~ and completely failed to recognize 
A l~4o (Figures 1 B and 1(3), suggesting that conforma- 
tional restriction may exist in the interaction between the 
antibody and AI~ molecules. The anti-Al~l.~ and anti-Al~.s 
antibodies seem to share similar amino-terminal specifici- 
ties because binding of both antibodies to A I~ was fully 
inhibited by the Al~l-s peptide, but not by AI~-7. 
The specificity of these antibodies was examined further 
as compared with other anti-AI3 antibodies using various 
modified synthetic AI~ peptides that have been shown to 
be present in AD brains (Figure 2). Surprisingly, neither 
the anti-Al~.s, the anti-Al~_~-7, nor the anti-Al~l.~ antibody 
reacted with the AI~I~ peptides bearing isomedzed or ra- 
cemized aspartate at the amino terminus. The anti-Al~.~ 
antibody differed from anti-Al~l-S in that only this antibody 
recognized the AP17-~ peptide. Because the anti-Al~l.~ anti- 
body failed to bind to the Al~7~o peptide, we may conclude 
that this antibody also recognizes the carboxyl terminus of 
the AI3x-~ peptide. The binding ofanti-AI3~.s and anti-Al~l~ 
antibodies to AI~ peptides does not seem to be influenced 
by the carboxy-terminal structure of the peptides, as both 
also recognized the AI~I.~ peptide. 
The anti-Ap~-~o antibody bound strongly to the APl~o and 
Ap~ peptides and more weakly to the others with varying 
degrees; the AI3~-~o peptide was barely recognized by 
this antibody. It should also be noted that the reactivity 
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(A) (B) Figure 3. Deposition of Distinct AJ) Species in 
Aged Brains 
Sets of serial cerebral sections (6 p.m thick) 
from 28 postmortem brains were immuno- 
stained using anti-AI),~, anti-AI3~0~_7, and anti- 
AJ)1_28 antibodies as indicated. (A) and (B) show 
representative s ctions taken from different in- 
dividuals. See the text for details. Bar, 1 mm. 
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of antisera raised against such a relatively large peptide 
bearing multiple possible epitopes is likely to vary de- 
pending on lots of the sera. The anti-AI)3~o antibody bound 
exclusively to A~ peptides ending with the 40th residue 
at the carboxyl terminus, whereas the anti-Al~.42 antibody 
bound only to AI)~-~. 
These data not only confirm the specificities of the anti- 
AJ)I-5 and anti-AI)~pE~7 antibodies toward their target mole- 
cules but also indicate that few anti-AI) antibodies react 
evenly with various forms of AI~ molecules in a strict sense. 
Terminal structures of the peptide seem to have profound 
influence on its binding of antibodies. This is probably 
because the antigenicity of synthetic AI) is heavier at the 
termini than other portions of the molecule. Consequently, 
the way AI~ peptides appear to us depends heavily on 
what kind of antibody we use to visualize them. We must 
therefore bear in mind that it is not easy to detect total AI) 
peptides impartially by immunochemical means and that 
use of anti-AI) antibodies with a narrow epitope range 
could result in negligence of certain forms of AI~ peptides. 
It is thus critical to employ well-defined antibodies for de- 
tecting specific AI) peptides in human brain tissues. 
Immunohistochemistry: Dominant Deposition 
of the Ap.~p~ Peptide in Senile Plaques 
Using this set of anti-Al~ antibodies, we performed immu- 
nohistochemical observations on serial sections from ce- 
rebral cortex so that their staining patterns could be com- 
pared directly (Figure 3). The postmortem brains used 
were from nondemented and demented individuals rang- 
ing in age from 68 to 99 years (average, 84.7; standard 
deviation, 10.0) and showing various degrees of amyloid 
deposition. Results can be divided into two major groups 
according to the relative density of the immunoreactive 
plaques. In one, approximately as many plaques were im- 
munostained by anti-AI31-5 (AI)N1 plaques) or anti-Al~l.~ as 
were stained by anti-Al3~pE~7 (A~N3(pE) plaques; Figure 3A). 
In the other, the AI~N~p~ plaques markedly exceeded the 
A~N1 plaques in density (Figure 3B). In only a few cases, 
the AI~N~ plaques slightly exceeded the AI)N~p~ plaques 
(see below). The anti-A~.5 and anti-AJ)1.28 antibodies 
showed similar staining patterns in accordance with their 
shared binding specificity toward the amino terminus of 
AI) (Figure 1). Other lots of anti-Al~.5 and anti-Al~-~7 anti- 
bodies raised in different rabbits gave similar immuno- 
staining patterns. 
To quantitate these observations, we counted the num- 
ber of plaques immunostained by each antibody in the 
cortical sections and plotted them against each other (Fig- 
ure 4). As shown in Figure 4A, the straightforward positive 
correlation in density between plaques immunostained by 
anti-AI)~.5 and by anti-AJ)l.2e (correlation coefficient, r = 
0.956) emphasizes the immunoreactive similarities of 
these antibodies. Figure 4B compares the densities of 
plaques immunostained by anti-Al~l-s and by anti-Al)~p~7, 
showing a much weaker correlation (r = 0.624). In this 
case, most of the data points are located around or above 
the 1:1 ratio line, substantiating the notion that AJ)N~pE) 
plaques are present in equivalent or greater densities than 
AI)N~ plaques. 
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Figure 4. Correlation i Density among A~ Plaques Immunostained 
with Anti-AI3~.~, Anti-A~l_28, and Anti-A~3(pEp7 Antibodies 
Sets of immunostained serial sections from 28 brains were photo- 
graphed, and the numbers of only distinct plaques, both the diffuse 
and compact types, were counted. 
(A) Correlation in density of plaques stained with ant-AI31_28 and those 
stained with anti-AI3~.~. 
(B) Density of anti-Al~(pE).?-reactive versus anti-A!5~.~-reactive plaques. 
The dotted lines indicate the points at which the densities of the 
plaques being compared equal each other. 
Biochemical Analysis of AlaN1 and AI}N3(pE ) Peptides 
in Brain 
To obtain a biochemical basis for the immunohistochemi- 
cal observation that the AI3N3(pE) plaques are present in 
brain in predominant or equivalent density as compared 
with the AI~N~ plaques (Figure 3; Figure 4), we performed 
Western blot analyses to quantitate these peptides ex- 
tracted by formic acid from brains (Figure 5; Table 1). We 
did not employ the method using high pressure liquid chro- 
matography and enzyme-linked immunosorbent assays 
(Suzuki et al., 1994), because A~N3(pE) peptides showed 
particularly poor recovery in reverse-phase chromatogra- 
phy and low solubility in an aqueous-phase chromatogra- 
phy (data not shown). The samples represent the brains 
in which AI3N3(pE) plaques are predominant (lanes 1-4) and 
those in which A~N1 and AI~N3(pE ) plaques are comparable 
(lanes 5-9) as immunohistochemically analyzed. Specific- 
ity of the antibody binding was confirmed by competition 
experiments as in Figure 1. 
The amount of AI3N~ varied from less than 0.05 to 30.5 
micrograms per gram of wet brain, whereas the amount 
of AI~N3(pE) varied from 5.6 to 91.0 micrograms per gram. 
Surprisingly, the latter was greater than the former in all 
the brains examined, indicating fairly ubiquitous presence 
of this amino-terminal modified form of AIS. These data 
also imply that the amount of AI3N3(pE) peptide per plaque 
may be greater than that of AI3N~ peptide. Furthermore, 
the results exclude the possibility that the immunohisto- 
chemical visualization may be more sensitive for detecting 
A~N3(pE) than for AlaN1, which could have resulted in overesti- 
mation of AI~N3(pE ) plaques. 
It is also clear that the amount of AI~N3(pE) relative to A~N1 
was significantly greater in the immunohistochemically 
A~N3(pE) plaque-dominant brains than in the brains in which 
AI3N~ and AI3N3(pE) plaques were present in comparable den- 
c123456789 
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Figure 5. Western Blot Analysis of A~N1 and A~N3(pE) Peptides in Formic 
Acid Extracts of Brain 
AI~ peptides were extracted by formic acid from frozen brain samples 
available for the analysis and subjected to Western blot analysis using 
the anti-AI31_s (A) and anti-A~3(pEl_7 (B) antibodies. Lane "c" contains 1 O0 
ng of the corresponding control synthetic peptides, AI3~ (A) and 
A~3ipE)~O (B). Lanes 1-4 represent the samples from brains with AJ3N3(pE1 
plaques being immunohistochemically dominant (plaque ratio of 
AI3N~pE) to AlaN1 > 1.5), while lanes 5-9 show samples from brains in 
which AI3N1 and A~N3(pE) plaques appeared comparable in density 
(plaque ratio < 1.5). Note that these samples were not necessarily 
taken from exactly the same brain areas as those used for immunohis- 
tochemistry. Three separate experiments wereperformed to confirm 
and quantitate the shown data (see Table 1). 
sities. These results agree with the immunohistochemical 
observation showing the dominant deposition of A~N3(pE) 
peptides in these brains. We must, however, point out that 
caution is required in interpreting these biochemical data, 
because efficiency of extraction may vary depending on 
the peptide species and because spatial information con- 
cerning the localization of the peptides (i.e., plaque amy- 
Ioid versus vascular amyloid) is lost by homogenization. 
Ratio Analysis of Immunohistochemical Data: 
Implications for Chronological Relationship 
between the ApN1 and AI~N3(pE) Plaques 
We further analyzed the immunohistochemical data to in- 
vestigate whether AI3N1 and AI~N3(pEI plaques are evolu- 
tionally related to each other. Figure 6 shows the relations 
between the density of AI3N1 or AI3N3(pE) plaques and the 
ratio of AI3N3(pE) plaques to AI3N~ plaques. The logical basis 
for this analysis lies in the assumption that each individual 
brain represents a various developmental stage of AI3 de- 
position, giving clues to resolving the processes in chrono- 
Table 1. Biochemical Quantitation f A~N1 and Ai~N3(pE) Peptides 
Extracted from Brains 
Peptide (~.g/g wet brain) Ratio 
Number A~N1 A~N3(pE) (A~N3(p JA~N1)  
AI~N3(pEI plaque-dominant brains 
1 3.2 35.0 10.9 
2 1.4 24.0 17.1 
3 >0.05 5.6 >112.0 
4 0.23 19.0 82.0 
AI3N1 and AI3N3<pEI plaque-comparable brains 
5 8.4 59.O 7.0 
6 2.1 17.0 8.0 
7 30.5 91.0 3.0 
8 3.0 17.0 5.7 
9 14.5 43.0 3.0 
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Figure 6. Ratio Analysis of A~N~ and A~N3(pE) Plaques 
Ratios of AI3N3(pE) plaques to AI~N~ plaques were calculated from the 
data shown in Figure 3B and plotted against the density of AI3N~ plaques 
(A) or the density of AI~NZ(pE) plaques (B) on logarithmic s ales. Linear 
regression analyses were performed to acquire the regression lines. 
The dotted lines indicate ratios of 1. r, correlation coefficient. 
Table 2. Density of A~N1 and AJ~N3(pE) Plaques in Brains from 
Down's Syndrome Patients of Various Ages 
Plaque Density 
(per 7.7 mm2)" 
Ratio 
Age/Sex A~N~ A~N3(pE) (A~ JAI3N3(pE)) 
31/M 0 6 0.00 
37/F 4 52 0.08 
38/F 23 173 0.13 
41/F 21 56 0.38 
42/F 80 161 0.50 
44/M 34 78 0.44 
53/M 24 25 0.96 
56/M 201 260 0.77 
57/M 328 241 1.36 
58/F 211 739 0.29 
59/M 50 126 0.40 
59/M 186 302 0.61 
62/F 484 332 1.46 
64/M 173 336 0.51 
a The numbers of plaques were counted as described in the legend 
to Figure 4. 
logical terms. The ratios and the densities of AlaN1 plaques 
are apparently well correlated (r = 0.765) on logarithmic 
scales; the ratios decreased and converged to 1:1 as 
plaque densities increased (Figure 6A). In contrast, no 
such tendency is apparent between the ratio and the den- 
sity of A~N3(pE) plaques (Figure 6B). These data suggest 
that AISN~ plaque formation was influenced by the ratio of 
A~N3(pE) to AISN~ plaques, whereas the AI3N3(~E) plaques arose 
in an independent manner. The most relevant interpreta- 
tion of this relationship in statistical terms would be that 
AI3N~ deposition followed AI~N3(pE) deposition in these brains. 
This possibility was examined further by comparing the 
plaque patterns in different cerebral cortical areas taken 
from the same individuals. 
A~N1 versus A~N3(pE) in Different Areas in Brain 
We examined 22 brains for which complete sets of frontal, 
temporal, and occipital sections were available for com- 
parison. In 4 cases, there was a clearly different relative 
plaque distribution depending on the brain area (Figure 
7). In 3 of these brains, the density of AI3N3(pE) plaques 
evidently exceeded the density of AI3N1 plaques in frontal 
and temporal lobes, whereas they were present in compa- 
rable densities in the occipital lobes. There was also 1 
case in which the AI3N3(pE) to AI3N1 ratio was greater in the 
occipital and temporal lobes than in the frontal obe. There 
were 7 other cases that showed weaker but distinct devia- 
tion in the relative immunoreactivity among the brain 
areas. 
Because the evolution of amyloid plaques may proceed 
at different rates within these brain regions before reach- 
ing overall saturation (Braak and Braak, 1991; Armstrong 
et al., 1993), these observations favor the assumption that 
AI3N3(pE) deposition precedes AI3N~ deposition in the course 
of plaque development. Furthermore, the anti-AI33(pE~7 anti- 
body reacted with diffuse plaques far more intensely than 
the anti-AI3~.~ antibody (compare the lower panels). This 
again indicates the presence of AI3N3(~E) peptide, rather 
than ALSN1, in early phases of amyloid deposition, since 
diffuse plaques represent an initial stage of senile plaque 
formation (Yamaguchi et al., 1989). 
AJ~m versus A~N3(pE) in Brains from 
Down's Syndrome Patients 
To examine further the above assumption concerning the 
chronological relationship between these AI3 species un- 
der conditions allowing a more straightforward interpreta- 
tion, we immunostained brain sections from Down's syn- 
drome patients of various ages. This is based on the 
knowledge that the extent of amyloid plaque formation 
relates far better to age in Down's syndrome than in normal 
aging and sporadic AD (Wisniewski et al., 1985; Oliver 
and Holland, 1986), even though the underlying mecha- 
nism for AI3 deposition may not necessarily be identical 
in a strict sense. 
Table 2 and Figure 8 summarize the immunohistochemi- 
cal observations of 14 Down's syndrome cases using the 
anti-AI31_~ and anti-A133(pE~7 antibodies. Most younger sub- 
jects under 50 years of age (Figure 8A) displayed very 
few anti-AI31.s-positive plaques. Even in these cases, the 
anti-Al3~pE)_7-positive plaques were clearly present in 
greater densities. Older subjects, i.e., over 50 years of age 
(Figure 8B), provided more variable results, with AI3N~pE) 
plaques being either equivalent or greater in density than 
AI3N1 plaques. Notably, the ratio of AJ3N1 to AISN3(pE) corre- 
lated significantly with age (ratio = 0.026 x age - 0.75; 
r = 0.64). These data firmly support the assumption that 
deposition of AI~N3(pE) precedes that of AI3N~. It should be 
noted, however, that A~N3(pE) may not necessarily represent 
the entire population of nonstandard AI3 molecules with 
modified amino termini present in these brains. Further 
studies focusing on other possible modifications (Roher 
et al., 1993a; Gowing et al., 1994) will be necessary to 
address this question. 
Differential Deposition of A~m and A~N3(pE) Peptides 
in Senile Plaques 
Finally, we investigated whether these A~ molecules dif- 
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ant i -A/3 ~.s ant i -A/3 3(pE)-7 Figure 7. Varying Relative Deposition of AI3 
Species, AlaN1 and A~N3(pE), in Different Cortical 
Areas from an Individual Brain 
Cerebral sections taken from the frontal, tem- 
poral, and occipital obes of a brain were immu- 
nostained with anti-Al~l+ and anti-AI3~Ep7 anti- 
bodies. Shown is 1 of the 4 brains within which 
the relative densities of the two plaque types 
clearly varied epending on the cerebral areas. 
See the text for details. Bar, 1 ram. 
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Figure 8. A~N1 and AJ3N3(pEI Plaques in Down's Syndrome Patients 
Serial sections from brains of Down's syndrome patients were immunostained with anti-AI31.5 and anti-AI33(pE~7 antibodies as in Figure 3. (A) and 
(B) show representative sections from young (38-year-old female) and old (58-year-old female) subjects, respectively. Bar, 0.5 mm. 
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Figure 9. Differential Deposition of AlaN1 and 
A~ Peptides in Individual P aques 
A set of serial sections immunostained as in 
Figure 2 are shown at greater magnification. 
A cerebral area showing typical, relatively mild 
A~ deposition (157 A~,I plaques and 277 Ap- 
N~-~ plaques per 7.7 mm 2) was chosen. See 
the text for definitions of arrows and arrow- 
heads. Bar, 100 p.m. 
anti- 
A/5' 3(pE)-7 
anti- 
A/3 1-28 
fering in amino-terminal structure are present together or 
separately in individual senile plaques. Figure 9 shows 
serial sections immunostained with the three anti-Al~ anti- 
bodies, at a greater magnification than the previous fig- 
ures. The anti-Al3~-s and anti-AI3~-28 antibodies bound to 
common plaques (as indicated by the arrows in the top and 
bottom panels), agreeing with the data given in Figures 
1-4. Plaques weakly stained only by the anti-AI3~-28 anti- 
body (upper left portion of the bottom panel) may contain 
a nonstandard AI~ peptide with the carboxyl terminus of 
A~x-28 (Figure 2). The anti-Al~pE~7-stained section (middle 
panel), sandwiched between the other two, shows a dis- 
tinct pattern. The plaques indicated by the arrowheads are 
anti-Al~pE~7-positive and anti-AI31.5-negative, while some of 
the plaques recognized by the anti-Al~l-s and anti-A[~l.28 
antibodies are not immunostained in this section. The 
other plaques, indicated by the arrows, seem to be com- 
posed of mixed AI~ peptides recognized by each of the 
antibodies. To summarize, some plaques consist exclu- 
sively of either AI3N1 or AI~N~pEI, while others contain both. 
This observation, together with the data suggesting an 
earlier deposition of A~N~pEI (Figures 3-8; Table 1 ; Table 
2), indicates that conversion of AI~N~ to AI3N3(pE) probably 
takes place prior to plaque formation, and that these differ- 
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ent molecular species of AI3 tend to aggregate through 
homophilic interactions, although they can also coaggre- 
gate. Once aggregated, the peptides will enter a solid 
state, under which any structural modification will proceed 
far more slowly than in solution. 
Discussion 
In the present stUdy, we have demonstrated that a distinct 
AI3 peptide, AI3N3(pEI, is deposited in senile plaques in a 
dominant and differential manner as compared with the 
standard AI3NI peptide. Both immunohistochemical nd 
biochemical data (Figures 3-5; Table 1) support this obser- 
vation. One advantage of our approach in detecting such 
a modified molecule in situ, as compared with the orthodox 
biochemical approaches, is that this approach minimizes 
any possible loss of the material that may otherwise result 
from peptide isolation procedures. Furthermore, the ratio 
analysis of the immunohistochemical data (Figure 6) and 
the regional difference of the AI3 deposition (Figure 7) led to 
the speculation that deposition of A~N3(pE) in senile plaques 
may have preceded that of AISN~. This possibility was 
strengthened significantly by the observation that AI~N~pE) 
plaques appeared earlier than AI3N~ plaques in Down's syn- 
drome brains (Figure 8; Table 2). 
Our results suggest that amino-terminal variations in AI3, 
in addition to the carboxy-terminal differences (Roher et 
al., 1993a, 1993b; Miller et al., 1993; Suzuki et al., 1994; 
Iwatsubo et al., 1994), must be taken into account when 
examining the pathological roles of AI3 peptides associ- 
ated, for instance, with depositability (Jarrett and Lans- 
bury, 1993) or neurotoxicity (Yankner et al., 1989; Mattson 
et al., 1993). We propose that A~3(pE)-4o and A~3(pE~2 pep- 
tides as well as AI31.,o and AI31-42 peptides be the subject 
of such studies. It is quite possible that AI33(pE)-42 is even 
more depositable than Al3~-42, because the former is ex- 
pected to be more hydrophobic owing to the loss of one 
positive and two negative charges (Figure 1). It is also 
likely that AI3N3(pE) has longer biological ife in tissues than 
other AI~ peptides with free amino termini, since the latter 
can be digested by various aminopeptidases while the 
former is sensitive only to pyroglutamate-specific ones. 
We should also not overlook other amino-terminal modi- 
fications of Al~, such as racemization, isomerization, and 
limited proteolysis at other sites (Roher et al., 1993a; Gow- 
ing et al., 1994). In addition, heterogeneous A~ peptides 
produced by cultured cells (Haass and Selkoe, 1993), par- 
ticularly by neuronal cells, should be considered. We are 
currently attempting to produce antibodies that will distin- 
guish these modified forms from one another and standard 
AI~; they should be useful in elucidating the evolutionary 
relationships among AI3 molecules possessing various 
amino-terminal structures. It is also critically important o 
produce or identify an "almighty anti-A~ antibody" that 
would impartially recognize any forms of A~, because all 
the antibodies used in the present study react differentially 
with various AI3 peptides (Figure 2). Accumulation of data 
based on both biochemical and immunohistochemical p- 
proaches should eventually lead to clarifying the AI~ pro- 
cessing associated with senile plaque formation. 
Because of the lack of such almighty antibodies, we do 
not know exactly what portion of the entire A~ population 
AI~N3(pE) constitutes. However, its amount relative to the 
standard AI3N1 peptide is significantly large (Table 1), indi- 
cating that it is probably one of the major species. We 
speculate that the following factors associated with isola- 
tion, identification, and analysis of AI3 may influence bio- 
chemical quantitation of modified AI3 peptides. First, the 
efficiency of extraction may vary depending on the peptide 
species. Second, anti-AI3 antibodies recognizing narrow 
epitope ranges of the antigen will neglect certain forms 
of AI3, as demonstrated in Figure 2. Third, reverse-phase 
chromatography of AI3N~pE) peptides, particularly AI3~pE)-42, 
results in low recovery. Fourth, AI~ peptides possessing 
a blocked amino terminus, such as acetylated AI3 and 
AI3N3(pE), are resistant o Edman degradation and thus are 
totally neglected in chemical sequence analyses, includ- 
ing radiosequencing. Fifth, tryptic digestion of AI3N~pE/pep- 
tides as a pretreatment for mass spectroscopic analysis 
results in the production of an amino-terminal fragment 
as short as a trimer, which may no longer be recovered in 
the subsequent reverse-phase chromatography. Isolation 
and characterization of AI3 peptides from senile plaques 
in the light of these possible factors will be necessary to 
assess the actual amount of nonstandard AI3 molecules, 
including AI3N3(pE~. 
Our current goal in AD research is to specify the pro- 
cesses directly involved in AD pathogenesis. Although we 
have not yet reached the point of defining the actual rate- 
limiting metabolic steps regulating senile plaque forma- 
tion, the present study provides new insights into future 
strategies. Because variations in both termini of Al~ seem 
deeply implicated regarding their ability to form plaques, 
we need to pay close attention to those proteases that 
influence the terminal structure of AI3 in the brain. These 
can be categorized into two groups on an enzymological 
basis. The first consists of two or more endopeptidases 
that cleave APP's and derivatives potentially producing 
A~ peptides with diversified termini. The other includes a 
number of amino- and carboxy-exopeptidases that directly 
modify the AI3 peptides. If AI3N3(pE) deposition proves to play 
a specific pathological role, the activity and localization 
of pyroglutamate-specific aminopeptidase(s) (McDonald 
and Barrett, 1986) may emerge as a candidate target for 
AD research. More specifically, we hypothesize that a re- 
duced pyroglutamate-specific aminopeptidase activity 
may possibly contribute to early senile plaque formation. 
Lastly, the homophilic tendency of AI3 aggregation (Figure 
9) implies that aggregation proceeds in a crystallization- 
like manner; local heterogeneity of AI3 metabolism could 
thus be an anti-AD factor working against plaque formation. 
Experimental Procedures 
Materials 
Brain tissues used for the present study were from 28 aged individuals 
(aged 68-99; average, 84.7 _+ 10.0) who displayed awide variety of 
senile plaque formation in terms of density. Because only 3 of them 
had been diagnosed with AD based on clinical and pathological criteria 
(McKhann et al., 1984; Khachaturian, 1985), we did not make any 
comparison l~etween AD and non-AD cases in the present study. For 
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Down's syndrome specimens, frontal cortices (Brodmann's area 8/9) 
were obtained at autopsy from 14 patients aged 31-64 years. 
Synthetic peptides were produced using a peptide synthesizer 
ACT350 or ACT396 (Advanced Chemtech) as described (Saido et al., 
1994a). The anti-A~l.28 (Kanemaru et al., 1990) and anti-A[51_5 (Saido 
et al., 1994a) antibodies have been described previously. An antiserum 
raised against A[51-~o (Antiserum 1282) was a generous gift from Dr. 
Dennis J. Selkoe (Haass et al., 1992). The antibody specific to A[SN3CpE) 
was produced using a synthetic peptide, pEFRHDC (A[531pE)-7 + C), 
conjugated to keyhole limpet hemocyanin and affinity-purified as de- 
scribed (Saido et al., 1992, 1994a). Other anti-A[5 antibodies, anti- 
A[53~o and anti-A~3~2, were similarly prepared using synthetic pep- 
tides, CVGGVV and CGVVIA, respectively. 
Immunohistochemistry 
Brains obtained from the aged individuals and Down's syndrome pa- 
tients were fixed in 10% buffered formalin for 1-4 weeks. Tissue blocks 
were cut, dehydrated, and embedded in paraffin, and serial sections 
were cut at 6 ~.m thickness. Sections were pretreated with 99% formic 
acid for 5 rain before immunostaining (Kitamoto et al., 1987). Consecu- 
tive sections were immunostained with anti-A[5 antibodies by the avi- 
din-biotin method using 3,3'-diaminobenzidine as chromogen and 
lightly counterstained with hematoxylin. The affinity-purified anti- 
bodies, anti-AI3~.s and anti-AI3 3(pE)-7, were used at a concentration of 
2.5 ~.g/ml, while the anti-A[5~_2B antiserum was used at 400-fold dilution. 
Biochemical Procedures 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE), Western blot- 
ting, and dot blotting were performed as previously described (Saido 
et al., 1992). Poly(vinylidene difluoride) membranes were used to im- 
mobilize blotted peptides. The affinity-purified antibodies were used 
at a concentration of 1 ~g/ml, and the antisera were used at 1000-fold 
dilution. Alkaline phosphatase-conjugated anti-rabbit IgG antibody 
(Tago) and alkaline phosphatase substrate kit (Vector Red; Vector) 
were employed for visualization of immunoreactivity. 
For biochemical quantitation of AI3 peptides in brains, we employed 
the following methods. Frozen cortices (1 g wet weight) were homoge- 
nized in a 10-fold volume of a buffer containing 10% SDS, 150 mM 
NaCI, 50 mM Tris-HCI (pH 7.5), 1 mM leupeptin, 1 mM diisopropyl 
fluoride, and 2.5 mM phenylmethylsulfonyl fluoride. The homogenates 
were centrifuged at 100,000 x g for 40 rain at 20°C. The pellets were 
collected and rehomogenized in 1 ml of 99.0% formic acid for 60 rain 
and centrifuged at 100,000 x g for 20 min at 20°C. The A[5-containing 
supernatants were vacuum-dried and solubilized in 500 ~1 of SDS- 
PAGE solubilization buffer containing 8 M urea and 5% I~-mercap- 
toethanoI, followed by heat treatment at 100°C for 3 rain. Aliquots (5 
Id) were subjected to Western blotting using a 5%-20% gradient gel 
as previously described (Saido et al., 1994a), except that a chemilumi- 
nescence method using peroxdase-conjugated anti-rabbit IgG anti- 
body (ECL kit, Amersham) was employed to visualize the immunoreac- 
tivity. The amount of the corresponding A~ species was quantitated 
by calibrating the blot densities against known amounts of synthetic 
A[5 peptides (Shoji et al., 1992). Three separate experiments were 
performed to confirm the results. 
Acknowledgments 
We are grateful to Dr. J. Saishoji (Insitute for Brain Research, Univer- 
sity of Tokyo) for assistance with immunohistochemistry and to Dr. M. 
Taniguchi (Institute for Comprehensive Medical Science, Fujita Health 
University) for the mass spectroscopic analysis of synthetic peptides. 
We also thank Dr. K. Yanagisawa (Institute for Brain Research, Univer- 
sity of Tokyo) and Dr. H. Nagata (Department of Molecular Physiology, 
Tokyo Metropolitan Institute of Medical Science) for valuable discus- 
sion. This work was supported in part by research grants from the 
Mitsui Life Social Welfare Foundation, the ONO Medical Research 
Foundation, the Naito Foundation, the Tokyo Metropolitan Institute of 
Gerontology, and the Ministry of Education, Science, and Culture of 
Japan. 
The costs of publication of this article were defrayed in part by 
the payment of page charges. This article must therefore be hereby 
marked "advertisement" in accordance with 18 USC Section 1734 
solely to indicate this fact. 
Received May 13, 1994; revised October 17, 1994. 
References 
Armstrong, R. A., Myers, D., and Smith, C. U. M. (1993). The spatial 
patterns of B/A4 deposit subtypes in Alzheimer's disease. Acta Neuro- 
pathol. 86, 36-41. 
Braak, H., and Braak, E. (1991). Neuropathological staging of Alzhei- 
mer-related changes. Acta Neuropathol. 82, 238-259. 
Glenner, G. G., and Wong, C. W. (1984). Alzheimer's disease: initial 
report of the purification and characterization of a novel cerebrovascu- 
lar amyloid protein. Biochem. Biochim. Res. Commun. 120, 885-890. 
Gowing, E., Roher, A. E., Woods, A. S., Cotter, R. J., Chaney, M., 
Little, S. P., and Bail, M. J. (1994). Chemical characterization of A~ 
17-42 peptide, a component of diffuse amyloid deposits of Alzheimer 
Disease. J. Biol. Chem. 269, 10987-10990. 
Haass, C., and Selkoe, D. J. (1993). Cellular processing of the 
~-amyloid precursor protein and the genesis of amyloid ~-peptide. Cell 
75, 1039-1042. 
Haass, C., Scholssmacher, M., Hung, A. Y., Vigo-Pelfrey, C., Mellon, 
A., Ostaszewski, B., Liederburg, I., Koo, F., Schenk, D., Teplow, D., 
and Selkoe, D. J. (1992). Amyloid [5-peptide is produced by cultured 
cells during normal metabolism. Nature 359, 322-325. 
Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., and 
Ihara, Y. (1994). Visualization of AJ~42(43) and A~40 in senile plaques 
with end-specific A~-monoclonals: evidence that an initially deposited 
A[5 species is AJ~42(43). Neuron 13, 45-53. 
Jarrett, J. T., and Lansbury, P. T., J r. (1993). Seeding "one-dimensional 
crystallization" of amyloid: a pathogenic mechanism of AIzheimer's 
disease and scrapie? Cell 73, 1055-1058. 
Kanemaru, K., Hasegawa, M., Shimada, H., and Ihara, Y. (1990). The 
presence of a novel protein in calf serum that recognizes [5 amyloid 
in the formalin-fixed section. Am. J. Pathol. 137, 677-687. 
Khachaturian, Z. S. (1985). Diagnosis of Alzheimer's disease. Arch. 
Neurol. 42, 1097-1104. 
Kitamoto, T., Ogomori, K., Tateishi, J., and Prusiner, S. B. (1987). 
Formic acid pretreatment enhances immunostaining of cerebral and 
systemic amyloids. Lab. Invest. 57, 230-236. 
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, 
B. L., and Beyreuther, K. (1985). Amyloid plaque core protein in AIzhei- 
mer's disease and Down syndrome. Prec. Natl. Acad. Sci. USA 82, 
4245-4249. 
Mattson, M. P., Barger, S. W., Cheng, B., Lieberburg, I., Smith- 
Swintosky, V. L., and Rydel, R. E. (1993). [5-Amyloid precursor protein 
metabolites and loss of neuronal Ca 2÷ homeostasis in Alzheimer's dis- 
ease. Trends Neurosci. 16, 409-414. 
McDonald, J. K., and Barrett, A. J. (1986). Pyroglutamyl peptidase I. 
Pyroglutamyl peptidase I1. In Mammalian Proteases, VoI. 2, Exopepti- 
dases (Academic Press, London), pp. 305-311. 
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., and 
Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease: report 
of the NINCDS-ADRDA Work Group under the auspices of Department 
of Health and Human Services Task Force on Alzheimer's Disease. 
Neurology 34, 939-944. 
Miller, D. L., Papayannopoulos, I. A., Styles, J., Bobin, S. A., Lin, 
Y. Y., Biemann, K., and Iqbal, K. (1993). Peptide compositions of the 
cerebrovascular and senile plaque core amyloid deposits of Alzhei- 
mer's disease. Arch. Biochem. Biophys. 301, 41-52. 
Mori, H., Takio, K., Ogawara, M., and Selkoe, D. J. (1992). Mass spec- 
trometry of purified amyloid 13 protein in Alzheimer's disease. J. Biol. 
Chem. 267, 17082-17086. 
Mullan, M., and Crawford, F. (1993). Genetic and molecular advances 
in Alzheimer's disease. Trends Neurosci. 16, 398-403. 
Oliver, C., and Holland, A. J. (1986). Down's syndrome and Alzheimer's 
disease: a review. Psychol. Med. 16, 307-322. 
Roher, A. E., Lowenson, J. D., Clarke, S., Wolkow, C., Wang, R., 
Cotter, R. J., Reardon, I. M., Zurcher-Neely, H. A., Heinrikson, R. L., 
Ball, M. J., and Greenberg, B. D. (1993a). Structural alterations in 
the peptide backbone of ~-amyloid core protein may account for its 
Neuron 
466 
deposition and stability in Alzheimefs disease. J. Biol. Chem. 268, 
3072-3083. 
Roher, A. E., Lowenson, J. D., Clarke, S., Woods, A. S., Cotter, 
R. J., Gowing, E., and Ball, M. J. (1993b). ~-Amyloid-(1-42) is a major 
component of cerebrovascular amyloid deposits: implications for the 
pathologyof Alzheimer disease. Proc. Natl. Acad. Sci. USA 90,10836- 
1 O840. 
Saido, T. C., Nagao, S., Shiramine, M., Tsukaguchi, M., Sorimachi, 
H., Murofushi, H., Tsuchiya, T., Ito, H., and Suzuki, K. (1992). Autolytic 
transition of pt-calpain upon activation as resolved by antibodies distin- 
guishing between the pre- and post-autolysis forms. J. Biochem. 111, 
81-86. 
Saido, T. C., Yokota, M., Nagao, S., Yamaura, I., Tani, E., Tsuchiya, 
T., Suzuki, K., and Kawashima, S. (1993). Spatial resolution of fodrin 
proteolysis in postischemic brain. J. Biol. Chem. 268, 25239-25243. 
Saido, T. C., Yokota, M., Maruyama, K., Yamao-Harigaya, W., Tani, 
E., Ihara, Y., and Kawashima, S. (1994a). Spatial resolution of the 
primary IB-amyloidogenic process induced in postischemic hippocam- 
pus. J. Biol. Chem. 269, 15253-15257. 
Saido, T. C., Sorimachi, H., and Suzuki, K. (1994b). Calpain: new 
perspectives in molecular diversity and physiological-pathological 
involvement. FASEB J. 8, 814-822. 
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, 
L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., and Youn- 
kin, S. G. (1992). Production of the Alzheimer amyloid ~ protein by 
normal proteolytic processing. Science 258, 126-129. 
Selkoe, D, J. (1993). Physiological production of the ~-amyloid protein 
and the mechanism of Alzheimefs disease. Trends Neurosci. 16, 403- 
409. 
Selkoe, D. J., Abraham, C. R., Podlinsky, M., and Duffy, L. K. (1986). 
Isolation of low-molecular-weight proteins from amyioid plaque fibers 
in Alzheimer's disease. J. Neurochem. 46, 1820-1834. 
Suzuki, N., Cheung, T. T., Cai, X.-D., Odaka, A., Otvos, L., Jr., Eckman, 
C., Golde, R. E., and Younkin, S. G. (1994). An increased percentage 
of long amyloid ~ protein is secreted by familial amyloid B protein 
precursor (IBAPP717) mutants. Science 264, 1336-1340. 
Wisniewski, K. E., Wisniewski, H. M., and Wen, G. Y. (1985). Occur- 
rence of neuropathological changes and dementia of Alzheimer's dis- 
ease in Down's syndrome. Ann. Neurol. 17, 278-282. 
Yamaguchi, H., Nakazato, Y., Hirai, S., Shoji, M., and Harigaya, Y. 
(1989). Electron micrograph of diffuse plaques, initial stage of senile 
plaque formation in the Alzheimer brain. Am. J. Neuropathol. 135, 
593-597. 
Yankner, B. A., Dawes, L. R., Fisher, S., Villa-Komaroff, L., Oster- 
Granite, M. L., and Neve, R. L. (1989). Neurotoxicity of a fragment of 
the amyloid precursor associated with Alzheimer's disease. Science 
245, 417-420. 
